A phase I multiple-dose, dose-escalation study to evaluate the safety of MEDI-507, a humanized monoclonal antibody that binds to the CD2 receptor, administered by subcutaneous injection to patients with plaque psoriasis
A phase I multiple-dose, dose-escalation study to evaluate the safety of MEDI-507, a humanized monoclonal antibody that binds to the CD2 receptor, administered by subcutaneous injection to patients with plaque psoriasis (PI: McCall, Co-I: Chen) 1% effort 3 subjects
Awarded By
- MedImmune MI-CP062
Contributors
- Chen, Suephy C Co-Principal Investigator
Amount
- $55,480.00
Start/End
- September 1, 2000 - April 30, 2002